Liquidia Technologies Inc

LQDA · Moat type: REGULIERUNG

MoatScore

2/10

Fair Value

n/a

Margin of Safety

n/a

Rating

MEIDEN

Liquidia Technologies develops and markets inhalable therapies for pulmonary arterial hypertension (PAH), with the commercially launched product YUTREPIA as the central revenue driver, whose revenues derive from direct sales to specialized pharmacies and treatment centers.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.